Larry Anderson, M.D., Ph.D.

Medical School	University of Texas Medical School at Houston (2000)
Internship	Mayo Clinic (2003), Internal Medicine
Fellowship	Fred Hutchinson Cancer Research Center (2006), Medical Oncology

• Bone Marrow Transplant & Stem Cell Transplants for Cancer
• Cancer

• Primary Interests
• Acute Leukemia
• Acute Lymphoblastic Anemia
• Acute Monocytic Leukemia
• Acute Myelogeneous Leukemia
• Acute Myeloid Leukemia (AML)
• Aplastic Anemia
• Aplastic Leukemia
• Burkett's Lymphoma
• Chronic Lymphocytic Leukemia (CLL)
• Chronic Myelogenous Leukemia
• Chronic Myeloid Leukemia (CML)
• Hematologic Malignancies
• Hodgkin's Disease
• Hodgkin's Lymphomas
• Leukemia
• Lymphoma
• Monocytic Leukemia
• Myelodysplasia
• Myeloid Leukemia
• Myeloma
• Non-Hodgkin's Lymphoma
• Plasma Cell Dyscrasia
• Stem Cell Transplantation

• Cancer immunology
• Immunotherapy
• MAGE-C1 (CT-7)
• Multiple Myeloma
• Stem Cell Transplantation

Featured Publications

Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate graft-versus-host disease and increases peri-BMT mortality.

Everse LA, Anderson LD Jr, Rooijen N van, and Mullen CA Transplantation March 2001 71 611-618

Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.

Anderson LD Jr, Mori S, Mann S, Savary CA, and Mullen CA Cancer Research October 2000 60 5797-5802

Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease

Anderson LD Jr, Savary CA, and CA Mullen Blood April 2000 95 2426-2433

Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine

Anderson LD Jr, Petropoulos D, Everse LA, and Mullen CA Cancer Research October 1999 59 1525-1530

HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells.

Anderson LD Jr, Hudson JM, Savary CA, Fisk B, Gershenson DM, and Ioannides CG Cancer Immunology Immunotherapy October 1999 48 401-410

Ganciclovir chemoablation of herpes simplex thymidine kinase suicide gene-modified tumors produces tumor necroses and induces systemic immune responses.

Mullen CA, Anderson L, Woods K, Nishino M, and Petropoulos D Human Gene Therapy September 1998 1998 2019-2030

DNA Immunization against the cerebral self antigen Amyloid beta 42 has high potential as safe therapy for Alzheimer’s Disease

Lambracht-Washington D, Qu B, Fu M, Anderson LD Jr, Stuve O, Eager TN, and Rosenberg RN Cellular and Molecular Neurobiology 2011 (In Press)

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of Multiple Myeloma

Anderson LD Jr, Cook DR, Yamamoto T, Berger C, Maloney DG, and Riddell SR Cancer Immunology Immunotherapy 2011 (In Press)

Adoptive T-cell therapy for B-cell malignancies

Hudecek M, Anderson LD Jr, Nishida T, and Riddell SR Expert Review of Hematology 2009 2 517-532

Use of Gene-Modified T-cells as Antigen Presenting Cells (T-APC) for Vaccination against Myeloma Antigens.

Anderson LD Jr, Cook DR, Berger C, Maloney D, and Riddell SR Blood November 2007 110 Abstract #2758

• ACS Institutional Research Grant
  Research Grant (2010)
• ASCO Young Investigator Award
  Research Grant (2006)
• K12 Career Development Award
  Research Grant (2006)
• Multiple Myeloma Research Foundation Fellow Award
  Research Grant (2006)

• American Society of Hematology